Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy

Diabetes Research and Clinical Practice
Hiroki YokoyamaMasae Kuramitsu

Abstract

In normal subjects, approximately half of the daily insulin requirement constitutes basal insulin. We investigated whether increasing the dose of insulin glargine up to half of the total insulin requirement could lead to better glycemic control in type 2 diabetic patients who were treated on basal-prandial insulin therapy. A total of 62 patients with type 2 diabetes on mealtime rapid-acting insulin analogue and bedtime NPH were randomized to either continuation of bedtime NPH (n=31) or morning glargine (n=31) for 6 months while continuing the aspart/lispro at each meal. The two groups were matched for age, sex, diabetes duration, BMI, HbA(1C), endogenous insulin secretion, and proportion of numbers using aspart/lispro and using oral hypoglycemic agents. The dose of insulin glargine was increased by 2-4 units to meet the target fasting blood glucose, whereas the dose of NPH was principally unchanged as a control group. Mean HbA(1C) at baseline was similar between patients with glargine and NPH (7.2% versus 6.9%). The percentage of glargine dose increased significantly (31% at baseline to 48% at 6 months) without any significant changes in total insulin dose. Mean HbA(1C) at 3 months was 6.6% with glargine and 7.0% with NPH (P<0....Continue Reading

References

Feb 1, 1988·The Journal of Clinical Investigation·K S PolonskyE Van Cauter
Apr 24, 2001·Diabetes Care·H Yki-Järvinen
May 8, 2003·JAMA : the Journal of the American Medical Association·Dawn E DeWitt, Irl B Hirsch
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators

❮ Previous
Next ❯

Citations

Oct 30, 2012·Endocrine·Luigi F Meneghini
Mar 18, 2011·Metabolic Syndrome and Related Disorders·Katherine EspositoDario Giugliano
Jan 30, 2009·Diabetes, Obesity & Metabolism·Mariëlle J P van Avendonk, Guy E H M Rutten
Aug 7, 2009·Wiener klinische Wochenschrift·Bernhard LudvikUNKNOWN Expertengruppe der Osterreichischen Diabetesgesellschaft
Oct 8, 2008·Current Medical Research and Opinion·Scott Nelson
Aug 27, 2011·Current Medical Research and Opinion·Scott E Nelson
May 23, 2008·Diabetes Research and Clinical Practice·Matteo MonamiEdoardo Mannucci
Oct 31, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·L A BazzanoV Fonseca
Jan 31, 2008·Diabetes/metabolism Research and Reviews·Patrick J Boyle, John Zrebiec
Apr 20, 2007·The Cochrane Database of Systematic Reviews·K HorvathA Siebenhofer
Apr 26, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Takahisa HiroseJacek Kiljański
Jun 5, 2007·Arquivos brasileiros de endocrinologia e metabologia·Frederico F R MaiaLevimar R Araújo
Nov 10, 2020·The Cochrane Database of Systematic Reviews·Thomas SemlitschKarl Horvath
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.